US EditionPublished • loading... • Updated
Boston Scientific to buy Penumbra in $14.5 billion deal
The $14.5 billion deal, valued at $374 per Penumbra share, aims to expand Boston Scientific's cardiovascular and neurovascular treatment offerings, addressing rising vascular disease rates.
- On Jan. 15, 2026, Boston Scientific announced it will acquire Penumbra in a $14.5 billion deal valuing Penumbra at $374 per share, said Mike Mahoney.
- To expand its cardiovascular portfolio, Boston Scientific will add Penumbra's comprehensive devices treating stroke, pulmonary embolism, and mechanical thrombectomy products like Lightning Bolt and Lightning Flash CAVT systems.
- Boston Scientific plans to finance the $14.5 billion cash portion with cash on hand and new debt, with Penumbra stockholders able to elect $374 or 3.8721 shares, and about 73% paid in cash.
- Completion requires Penumbra stockholder approval and customary conditions, with the transaction expected to be $0.06-0.08 dilutive to adjusted EPS in year one and closing in 2026.
- Boston Scientific said the deal could broaden patient access as Penumbra expects fourth quarter growth of 21.4%- 22.0% and full year 2025 revenue near $1.4 billion, with CEO Adam Elsesser highlighting "decades-long development".
Insights by Ground AI
16 Articles
16 Articles
Boston Scientific inks $14.5B deal, boosting its Minnesota-dominated heart device portfolio
Boston Scientific has long used mergers and acquisitions to fuel growth. But this deal appears be to company’s largest since its acquisition of pacemaker company Guidant in 2006 for $27 billion.
·Minneapolis, United States
Read Full Article
Coverage Details
Total News Sources16
Leaning Left2Leaning Right1Center9Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 17%
C 75%
Factuality
To view factuality data please Upgrade to Premium
